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Differences in outcomes indeed exist among trans-
plant programs and organ procurement organizations
(OPO). A growing set of tools are available from the
Scientific Registry of Transplant Recipients (SRTR) to
measure and assess these outcomes in the different
phases of the transplant process. These tools are not
intended to compare two individual programs, rather
to help identify programs whose practices may need
further scrutiny, to be either avoided, corrected or em-
ulated.
To understand which differences in outcomes might
be due to underlying differences in populations served
and which might be due to differences in treatment,
it is important to compare outcomes to ‘risk-adjusted’
expected values. Further, it is important to recognize
and assess the role that random chance may play in
these outcomes by considering the p-value or confi-
dence interval of each estimate. We present the reader
with a basic explanation of these tools and their inter-
pretation in the context of reading the SRTR Program-
Specific Reports.
We describe the intended audience of these reports,
including patients, monitoring and process improve-
ment bodies, payers and others such as the media.
Use of these statistics in a way that reflects a basic
understanding of these concepts and their limitations
is beneficial for all audiences.
Key words: Program-specific, risk-adjustment, SRTR,
survival, transplant outcomes
Introduction
The Transplant Program- and OPO-Specific Reports pub-
lished by the Scientific Registry of Transplant Recipients
(SRTR) are intended to help evaluate whether the nation’s
organ transplant system is efficient at providing optimal
care to patients, especially given the constraints on the
precious resource of donor organs. These reports pro-
vide a range of performance outcomes at the nearly 1000
transplant programs and organ procurement organizations
(OPOs) that participate in the Organ Procurement and
Transplantation Network (OPTN). Their public availability
provides the opportunity for any audience to see which
transplant programs are not transplanting candidates as
quickly as expected, which programs have high posttrans-
plant survival rates and which OPOs recover different types
of organs at the highest rates.
The reports themselves are part of a whole family of
tools, consistent in their statistical approach, that are used
by multiple audiences to help understand the outcomes
achieved in different phases of the transplant process. As
the statistics included in these reports are used increas-
ingly by various audiences—the OPTN Membership and
Professional Standards Committee, CMS and private in-
surers, the popular press and patients and families—many
readers have requested a closer look at their interpreta-
tion. This article takes the new reader of these reports
through many of the statistics included and addresses
some of the most common questions raised about these
reports.
Hereafter, we generally refer to these reports as ‘Program-
Specific Reports’ unless specifying those for transplant
programs or OPOs.
We aim to explain basic themes included in these reports
to readers who are new to these statistical concepts, and
provide an overview for readers who are familiar with the
concepts but not with their application in this area. For
readers seeking more technical detail, further explanations
have been previously published (1) and are also available
in the ‘Background and Methods’ section of the Program-
Specific Reports at www.ustransplant.org.
We start by surveying the range of statistics that describe
the different parts of the transplant process, then address
the following questions:
1012
Guide to Program-Specific Reports
(i) Are there really differences among transplant pro-
grams and OPOs? In types of performance measure-
ments?
(ii) Are the differences we observe among programs
merely due to differences in patients, donor organs or
random chance? What role does ‘risk adjustment’ play
in helping us distinguish these from differences that
can be attributed to the transplant program or OPO?
(iii) Who are the audiences for the reports, and how do
they use the reports for performance measurement?
(iv) How should these measures affect transplant program
or OPO behavior?
Which Statistics and Parts of the Transplant
Process Are Covered?
The organ procurement and transplantation process is
complex with many trade-offs in outcomes. The Program-
Specific Reports present characteristics and outcomes of
multiple stages of the transplant process, without value
judgment about these trade-offs. For example, a transplant
center may be able to transplant a high number of its wait-
listed patients, at the expense of poorer transplant out-
comes that arise from the use of less ideal organs. How-
ever, a donor organ with many donor comorbidities may
be better for a given candidate than waiting and perhaps
receiving none at all.
Figure 1 gives an overview of these stages and the mea-
sures presented in the reports, intended to help evaluate
the efficient operation of the transplant system and effec-
Procurement  of Donor  Organ s
Identification of  eligible deaths (OPO Table 3)
Donors procured per eligible death (OPO Table 3)
Organs procured per donor (OPO Table 1)
Care for Patients Awaiting Organs
Transplant rate from the waiting list (OPO 6,7; TPSR 
3,4,5,6)
Mortality rate after wait-listing  (TPSR 3,4)
Organ acceptance by Transplant Program (TPSR 3a)
Post-Transplant Outcomes
Graft survival after transplantation (TPSR 10)
Patient survival after transplantation (TPSR 11)
Transplant Operation
Source: SRTR
Figure 1: Phases and measures presented in the Program-Specific Reports.
tive use of a limited supply of organs to answer a growing
demand.
The outcomes listed in the top left box, ‘Procurement
of Donor Organs’, help us answer questions pertaining
to the first stage in the process defining efficient use
and optimal patient care: identification and procurement
of donor organs. An OPO and the hospitals with which
it works are primarily responsible for identifying eligible
donors from among the in-hospital deaths, working to
ensure that appropriate candidates become donors, and
seeing that, if possible, all of the available organs from
a procured donor are used. Measures of these three
outcomes are shown in the OPO-specific reports, and
the implementation of currently planned expansion of
data collection for eligible donors will help refine these
measures.
The top right box, ‘Care for Patients Awaiting Organs’, also
reflects whether a limited supply of available organs is be-
ing used efficiently, and how close that supply meets the
demand, this time more from a patient’s point of view.
Though the transplant program may not be the primary
direct caregiver before the transplant takes place, charac-
teristics and practices at the center and within the dona-
tion service area (DSA) may influence how long the patient
waits for a suitable organ, and the patient’s chances for sur-
vival during that time. The primary waiting list outcomes—
transplant rate and mortality rate—may indicate a center’s
willingness to accept higher risk organs, the OPO’s ability
to find organs or even the rate at which potential organ
donors become available.
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The bottom box, ‘Post-Transplant Outcomes’, addresses
questions regarding the last stage of the transplant pro-
cess by measuring posttransplant graft and patient sur-
vival. Outcomes at 1 month, 1 year and 3 years after
transplant all reflect the risk of the transplant operation,
as well as immediate- and long-term follow-up care.
In addition to the outcomes listed in Figure 1, the reports
also give descriptive background about the populations
served by each program or OPO. For transplant programs,
different tables show profiles of the wait-listed patients and
transplant recipients, as well as profiles of the donors cho-
sen for transplant. For OPOs, different tables describe the
geographic areas served by the OPO, the characteristics of
the donors and organs procured and which transplant pro-
grams eventually use organs recovered by the OPO. These
descriptive tables provide background to the outcomes ta-
bles that we focus on here.
Why Program- or OPO-Specific? Are There
Really Differences Among Programs?
Differences do indeed exist among programs. As an exam-
ple, Figure 2 shows unadjusted 1-year kidney graft survival
after deceased or living donor transplant. The heights of
the vertical bars represent the number of transplant failures
per 10 transplants performed at each of the 238 different
kidney transplant programs in the country. Six programs,
at the left end of the figure, had more than two failures
per 10 transplants, corresponding to 1-year graft survival
of less than 80%. At the other end, 24 programs had no
failures among their transplants.
In between, we see wide variation of transplant survival
around the horizontal line indicating the national average
of 0.74 failures per 10 transplants, or about 93% survival.
Fully one in four programs experience graft survival at or






























Source: SRTR Transplant Program Specific Reports, published July 
2007.  Includes deceased and living donor transplants performed in the 
2.5 years ending 6/30/2006.
Figure 2: Unadjusted graft failures per
transplant.
1-year graft survival rates above 95%. There is a fairly large
difference between the top quarter of programs and the
bottom quarter.
Similar variation exists among all of the outcomes listed in
Figure 1, and for graft and patient survival for other organs.
One must be careful in interpreting such differences, be-
cause these differences could arise from several factors:
(i) Differences among the patients served by the center:
for example, one center may treat patients who, on
average, are older or more severely ill than most other
centers, and therefore expect lower survival.
(ii) Differences in the characteristics of the donors avail-
able: some donor organs are higher quality than others,
and some centers may have access to donors that are a
better match for its patients—or simply to more donors
overall.
(iii) Differences in treatment practices: some transplant
teams may be more experienced or skillful, or oth-
erwise provide better care both during and after the
transplant operation. The care received outside of the
transplant center may also be of variable quality.
(iv) Random variation: sometimes centers experience
poor, or excellent, outcomes just as a matter of ran-
dom chance, particularly for smaller programs.
To disentangle the differences of interest from those that
might only confuse the question, we use a process called
‘risk adjustment’, which we describe in the next section.
In the case of determining which programs provide excel-
lent care or need improvement, the differences of interest
are those due to variations in patient treatment; we will
risk-adjust for measured and reported patient and donor
characteristics that might otherwise confuse our results,
and thereby exclude these differences from our compar-
isons.
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What Does Risk Adjustment Mean?
Risk adjustment is a statistical method through which we
can factor out differences in outcomes that reflect differ-
ences among patients or donors in order to infer the mag-
nitude of differences due to treatment practices. The use
of risk adjustments allows us to answer questions such as:
‘What is the survival we observe at this program,
and how does it compare to what we would ex-
pect based on typical results for the types of patients
served and donors used’?
This question has two important features. First, the main
focus is on the ‘simple’ actual survival rate achieved and
observed for the transplant program. However, this fram-
ing of the question also emphasizes that the actual sur-
vival rate must be compared to what would be expected
for the ‘case mix’ of patients served and donors used, in
order to avoid attributing poor (or good) outcomes that are
associated with this case mix to the program’s treatment
practices instead.
Risk adjustment is a quantitative or statistical process that
helps us to account for differences in patients and donors
in making a more valid comparison of other factors, such as
treatment practices. The next several paragraphs explain
the use of risk adjustment with practical examples from
the transplant community.
A simplified example: adjusting for recipient age
To help understand how we calculate expected outcomes,
and to illustrate why it is important to do so, consider the
example of how the ages of the transplant recipients may
affect a transplant program’s outcomes. In this simplified
illustration, we will assume that all patients and donors are
alike, except that they have different ages. Figure 3 shows
our calculation, beginning with the national observed pa-
tient survival for two adult age groups, taken from the 2006
OPTN/SRTR Annual Report. Adults under age 65 had much
higher survival, 79% at 3 years, than did those over 65,
71% at 3 years following transplant. Because only one in
10 adult liver recipients was over 65, the national average
survival rate was very close to the rate for these younger
% in group % survival Survivors Survival %
Observed
Age 18-64 90% 79% 10            9             90.0%
Age 65+ 10% 71% 90            66           73.3%
%0.57%87llarevO
Expected
01X%9746-81 egA             = 7.9




Source: Analysis based on 2006 OPTN/SRTR Annual Report, Tab le 
9.12a  
Figure 3: Simple age adjustment for 3-year
liver survival.
recipients, at 78% (which is the ‘weighted average’ be-
tween the 79% for 90% of recipients and 71% for the
other 10%).
Unlike the nation as a whole, the sample transplant pro-
gram shown in the three columns to the right treats mostly
patients older than 65, or 90 of the 100 patients trans-
planted. Nine of 10, or 90%, of their younger patients sur-
vived, as did 66 of 90 (73%) of their older patients. Both
groups of patients at this center did better than the corre-
sponding groups in the nation, yet a simple comparison of
the overall survival rate shows this center, at 75%, falling
below the national average of 78%.
The lower panel shows the calculation of the expected
survival rate, which allows us to make a proper compar-
ison between program-specific and national experience.
For the 10 younger patients, we can expect a 79% survival
rate based on the national experience, or that 7.9 patients
should survive; for the 90 older patients, we expect 71%
or 63.9 to survive. Together, we expect 71.8 survivors or
71.8% of the total 100 transplants. The favorable compari-
son of the center’s survival of 75% to the expected survival
of 71.8% is consistent with the results we find for each age
group. Had we not used risk adjustment for age to account
for the older patients served by this center, we might have
improperly characterized this program as under-performing
with respect to patient survival, when in fact they are ac-
tually performing better than expected in treating a more
challenging patient mix.
Risk adjustment by within-group comparison
OPO-specific report Table 1 measures both the number
of organs recovered for transplant and the number trans-
planted, both expressed as ‘per donor’. This table illus-
trates simple risk adjustment by comparison within group,
as shown in the example of age-adjustment above. The av-
erage number of organs per donor is calculated separately
for standard criteria donors (SCD) as well as expanded cri-
teria donors (ECD) and donors after cardiac death (DCD). By
reporting these averages separately for each donor type,
we can compare the organ yield for an OPO against a na-
tional average for similar donors. Just as in the age ex-
ample above, to fairly characterize the per donor count of
organs for an OPO that procures organs from many ECDs,
donor-type specific comparisons must be made because
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Table 1: Effect of expanded criteria donor definition components




Creatinine (per 1 mg/dL) 1.10
Donor age: 65+ (ref = 35–49) 1.49
COD stroke (vs. head trauma) 1.31
‘ECD’ classification 1.08
Calculated as exp (Beta) from 1-year kidney graft survival model,
CSRs released 01/11/2007.
Source: SRTR.
the lower yield among ECDs may detrimentally decrease
the overall average for the OPO that procures more ECDs
than average.
Similarly, report Table 5 of the transplant Program-Specific
Reports adjusts measurements of waiting time until trans-
plant by analyzing this calculation separately for wait-listed
patients with different characteristics. The characteristics
chosen include those that may likely influence the time
until transplant, such as disease severity or immune sen-
sitivity.
Risk adjustment for multiple factors by regression
model
In the Program-Specific Reports, the tables showing graft
and patient survival, waiting list outcomes, and donation
rates use a more complex adjustment method to account
for the many patient and donor factors that should be in-
cluded in the risk adjustment. To simultaneously adjust for
a long list of factors in the same way that age is controlled
for above, the SRTR uses a statistical technique called the
Cox regression model (2).
The Cox model uses observations of all the patients and
donors in the country, and their characteristics and out-
comes, to estimate the effect of each characteristic on
outcomes. We then apply these estimated effects to each
patient-donor combination, allowing us to calculate an ex-
pected outcome for each patient, which can be added
together for all patients treated by a transplant program.
This effect is how each factor is ‘weighted’ in the risk-
adjustment process. A broader description of the factors
selected follows later in this article.
For example, many programs use ECD kidneys for recipi-
ents who are likely to die before having the opportunity to
receive a non-ECD kidney. To ensure that the lower survival
rate associated with these donors does not, on its own, in-
dicate poor performance for the transplant program as a
whole, we incorporate these donor factors into the mod-
els for expected survival. Table 1 shows the factors used
in identifying an ECD kidney and their separate effects on
1-year graft survival. Not all ECD kidneys are characterized
by all of these factors. A kidney from a donor with a history
of hypertension, whether classified as ECD or not, carries
with it a risk of graft failure 1.18 times that of an organ from
a donor without hypertension, or 18% higher risk (Table
1). That is, if a patient with an organ from a nonhyperten-
sive donor had a probability of graft loss at 1 year of 0.05,
then the same patient with a hypertensive—but otherwise
similar—donor would have a probability of graft loss at 1
year of 0.05 × 1.18 = 0.059. If that same donor were also
older than 65, the kidney would be another 1.49 times as
likely to fail compared to a donor between 35 and 49, for
total elevated risk of 1.18 × 1.49 = 1.76. By multiplying the
hazard ratios listed, note that a kidney from a donor with
all of the characteristics listed in Table 1 represents a graft
failure risk more than three times that of a kidney from a
donor with none of these characteristics.
Reading and interpreting a risk-adjusted table
Figure 4 shows excerpts from a recent Program-Specific
Report for a liver transplant center. As was the case in
the simplified age example presented above, the reader
should be careful to compare the center’s outcomes to
those expected based on risk adjustment, rather than the
unadjusted national average.
In this particular example, the center achieves a posttrans-
plant survival percentage at 1 year of 87.78% (line 3). This
is higher than the national average of 86.26% (line 3), but
lower than the expected survival of 89.41% (line 4). The
following conclusions seem logical to make:
(i) The expected survival rate at this center is higher than
the national average, suggesting that the types of pa-
tients treated at this facility, or the types of donors used
by this facility, typically have above-average outcomes.
(ii) The survival rate we observe as achieved by this center,
while higher than the national average, is not as high as
might be expected given the typical results for similar
patients in the rest of the nation.
(iii) Had no risk adjustment been performed, a comparison
to the national average would be misleading.
This panel of the Program-Specific Reports table formu-
lates statistics from the perspective of a user asking to
estimate the chances that a patient would be living 1 year
after transplant surgery, if transplanted at a specific center.
Standardized ratios
Lines 5–10 of the table in Figure 4 show another perspec-
tive that can be interpreted to find the fraction of excess
events (or percentage shortage of events). The ‘standard-
ized ratio’ is the number of observed events (deaths af-
ter transplant, graft failures, transplants, deaths after wait-
listing or organ donors procured) divided by the number
of those events that would be expected, according to the
risk-adjustment model and time followed.
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Center National
Line 1 Year 1 Year
1 Transplants (n=number) 90 10,781
2 Percent (%) of Patients Surviving at End of Period
3    Observed at this Center 87.78 86.26
4    Expected, based on national experience 89.41
5 Deaths During Follow-up Period
293,111retnec siht ta devresbO   6
7    Expected, based on national experience 8.48 1,392
8    Ratio: Observed to Expected (O/E) 1.30 1.00
9       (95% Confidence Interval) (0.65-2.32)
10    P-value (2-sided), observed v. expected 0.469
11
How does this center's survival compare to




13 Follow-up days reported by center (%) 91.7 93.9
563563)n( pu-wolloF fo syaD mumixaM41
Adult (Age 18+)
Source: SRTR Program-Specific Reports, www.ustransplant.org
Figure 4: Program-Specific Re-
port table 11—patient survival
after transplantation, Sample
Liver Center.
A standardized ratio equal to one indicates that the fa-
cility performed exactly as expected, given its case mix.
Note that ‘events’ may be good (transplants from the
waiting list, organ donors procured) or bad (deaths or
graft failures). In the case of adverse events, such as
the ‘deaths during the follow-up period’ shown in Figure
4, standardized ratios above one indicate worse than ex-
pected performance, while standardized ratios below one
indicate better than expected performance. Conversely, for
a good outcome such as transplant from the waiting list,
the interpretation goes in the other direction: a standard-
ized ratio above one would indicate better than expected
performance.
Additionally, this ratio easily conveys the extent of the dif-
ference from the expected outcome, in this case the ratio
of excess deaths. In Figure 4, 11 deaths were observed
(line 6), compared to 8.48 expected (line 7), for a standard-
ized ratio of 1.30. We observed 1.30 times as many deaths
as we expected or 30% more. If the ratio were below one,
it can be interpreted as the fraction of expected deaths; for
example, a standardized death ratio of 0.80 indicates that
we observe 0.80 deaths per expected death or 20% fewer
(1–0.8 = 0.2).
Unlike the comparison of the percentage of patients surviv-
ing, the counts of observed and expected events used in
the standardized ratio also take into account the timing of
an event, and reflect an advantage for longer survival within
the time period examined. For example, compare a patient
who dies 1 day after transplant with a patient who dies 365
days after transplant. Each of these has the same effect on
percentage surviving after 1 year, and each contributes one
death to the numerator of the standardized ratio. Since the
denominator of the ratio, the expected number of deaths,
is much higher after 365 days, the adverse effect of the
early death is weighted more heavily (3).
Limitations of risk adjustment
The risk-adjustment process can only account for differ-
ences among patients and donors that are measured and
reported completely and accurately for patients across all
transplant programs. Some characteristics that would likely
impact posttransplant outcomes are not collected by the
OPTN data collection process or the other sources used (3),
because of the need to balance full adjustment with the
burden of data collection. Though many clinical features
affect patient survival, calculating—and adjusting for—the
effect that those features ‘usually’ have on patients re-
quires evidence from all programs and patients. Granular or
even major differences in severity of illness or donor quality
cannot be adjusted for if they are not reported uniformly
across all centers. Examples might include the presence
of interstitial fibrosis on the biopsy of a donated kidney or
a measure of the severity of a recipient’s coronary artery
disease: though these factors surely affect survival, they
are not reported in the data sources available.
Even when data are available, practices or characteristics
that are exhibited only at a small number of programs are
difficult to incorporate into the risk-adjustment process be-
cause no ‘typical national experience’ can be defined. It is
therefore hard, or even impossible, to adjust for the risk of
some new or experimental procedures because no ‘typical’
experience can be established from other programs.
Given the limitations of risk adjustment, as well as the role
of random chance discussed later, it is useful to look at how
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well the models we have perform. For survival models,
the index of concordance (IOC) is used to measure how
well the model predicts the outcomes. Specifically, of the
number of patient pairs for which the ordering of the failure
times is observed, the IOC is the percentage of observed
orderings that are consistent with the orderings predicted
by the model. The IOC can be interpreted as reflecting the
percentage of variation in outcomes that is predicted by
the factors included for risk adjustment; the remainder of
the variation being due to the effects of treatment practices
at the transplant program, as well as to unmeasured or
unreported risk factors and random chance. For models
released in January 2008, indexes of concordance range
from 56% to 93%. The vast majority of the 44 models
(for different organs, donor types and follow-up periods)
had IOCs between 60% and 75%, leaving 25% to 40%
of the variation due to unmeasured or unreported factors,
treatment effects and random chance. IOCs are published
along with the estimated effects of each risk adjustment
factor in the PSR website section titled ‘Risk Adjustment
Models’.
After Risk Adjustment, Are There Still
Differences Between Programs?
At the start of this article, we asked the question of
whether there really are differences in outcomes among
transplant programs. As exemplified by Figure 2, there
Figure 5: Comparison of unadjusted to adjusted graft failure ratios among kidney transplant programs.
can be tremendous variation in unadjusted outcomes. We
now look at whether those differences ‘disappear’ when
we look at adjusted statistics; whether the outcome differ-
ences we saw in Figure 2 are all due to patient and donor
characteristics that can be risk-adjusted or ‘controlled for
in the model’.
In Figure 5, we show an unadjusted graft failure ratio, sim-
ilar to the standardized ratio described above, but with-
out case mix adjustment (the expected value is the simple
national average, not depending on the types of patients
served). This unadjusted ratio is the line in the background
from the highest ratio (most graft failures per transplant)
on the left to the fewest on the right, and mirrors the shape
of the distribution shown in Figure 2. The horizontal line at
observed/expected (O/E) = 1 identifies where each facility
would be if it experienced exactly as many graft failures
as expected. Note that the horizontal line represents, for
the unadjusted survival, the same concept that it did as the
national average in Figure 2: for an unadjusted statistic, the
expected value is the national average.
Each dot (triangular or round) represents the standardized
graft failure ratio for each program, risk-adjusted for case
mix. For any center, the impact of risk adjustment is mea-
sured by the distance along a vertical line drawn through
that center’s adjusted value (dot), and its unadjusted value
(line). After adjustment, about 45% of transplant programs
move down (or up) into the shaded area of the graphic and
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Table 2: Risk-adjusted tables, methods and factors in the SRTR Program-Specific Reports
Report, table, name Adjustment Adjustment factors








Age, race, gender and cause of
death among notifiable deaths
Donor conversion from
eligible deaths
OPO Table 3: ‘Donation Rate’ Regression model with
comparison to expected
Notification rate, hospital
characteristics such as presence
of a trauma center. National data
are not currently available on the
characteristics of the eligible
deaths.
Organs procured per donor OPO Table 1: ‘Organs
Recovered/ Transplanted
per Donor’
Within-group comparison Comparison to national average
separate for Standard Criteria
Donor, Expanded Criteria Donors
and Donation after Cardiac Death
Transplant rate from the
waiting list
Transplant program report,
Table 3: ‘Transplant Rate’
Regression model with
comparison to expected
Age, blood type, previous transplant,
immunological sensitivity, primary
disease, medical urgency status or
disease severity
Transplant program report,
Table 4 and OPO Table 6:
‘% transplanted by a given
time’
Within-group comparison Age, blood type, previous transplant,
immunological sensitivity, primary
disease, medical urgency status or
disease severity
Mortality rate after wait-listing Transplant program report,




Age, blood type, previous transplant,
immunological sensitivity, medical








Donor factors (demographics, history
of related illnesses, cause of
death, organ function measures);





sensitivity, other health status
indicators, insurance);
‘Patient Survival’ Donor-recipient match characteristics
(antigen mismatches and blood
type compatibility, cold ischemic
time, compatibility of body size)
Source: SRTR.
toward the horizontal ‘expected’ line; these are transplant
programs for which case mix factor explains a portion of
the variation in performance.
For another 45% of transplant programs, the risk-adjusted
ratio is even farther from one than its unadjusted counter-
part; these are the darkened triangles. That is, differences
in outcome among facilities may persist or even become
more pronounced upon taking into account these patient
and donor factors.
Sometimes the interpretation completely changes as a re-
sult of risk adjustment. These are the 10% of programs,
indicated by round dots, which move all the way across
the shaded area. For these, risk adjustment changes the
overall interpretation from better performance to worse (or
vice versa). Just as in the age example presented earlier, an
accurate picture is obtained only by looking at risk-adjusted
values.
Which Statistics Are Risk Adjusted?
Above, we outlined two different approaches to risk ad-
justment, both used in the SRTR OPO- and Transplant
Program-Specific Reports: adjustment via a ‘comparison
within-group’ or stratified analysis, and the use of a re-
gression equation to adjust for multiple factors simultane-
ously. Table 2 lists which statistics in these reports are
risk-adjusted, which method is used and overviews of the
factors used for adjustment.
Note that adjustment factors differ for each organ. More-
over, the set of adjustment factors for a given organ
may differ across reports, since the models are under
frequent review by the SRTR. For a detailed list of cur-
rent adjustment factors, see the risk-adjustment model de-
scription tables in the ‘Background and Methodology’ sec-
tion of the Program-Specific Reports at www.ustransplant.
org.
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How Are the Factors for Risk Adjustment
Determined?
Risk adjustment helps determine what results we would
expect for ‘similar’ patients, according to the national ex-
perience. But what variables define similarity for our risk
profile? The following list identifies risk factors that may
impact posttransplant outcomes, and how likely they are
to be appropriate for risk adjustment.
Patient characteristics? Almost always. Adjusting for pa-
tient characteristics helps ensure that centers are not pe-
nalized for treating patients who are more likely to have
poor outcomes. For example, the age of the recipient is
closely associated with outcomes, and not controlling for
age might penalize centers that treat older patients, either
as an explicit protocol element or due to the age distribu-
tion of the geographic area served.
Donor characteristics? Usually. Given a very short supply of
organs available for transplant, programs and patients often
decide to use an organ that is not optimal, determining that
having this organ is better for the patient than remaining on
the waiting list. Adjusting for a range of donor organ charac-
teristics helps ensure that programs are not penalized for
these decisions. For example, more and more centers are
using ECD kidneys for patients who may be better off with
those organs than lingering on the waiting list; by not con-
trolling for these characteristics, which by definition result
in elevated risk of graft failure, we would unfairly compare
outcomes of ECD and non-ECD recipients, which might
discourage the use of ECD organs.
Characteristics of the donor-recipient match? Much of the
time. These characteristics include things like the blood
type or antigen compatibility between the donor and recip-
ient. Like other donor characteristics, transplant programs
may need to accept organs that are imperfect matches.
There is a trade-off between adjusting for compromises in
choices about the donor, and adjusting for poor choices on
the part of the transplant program.
Transplant center characteristics? Usually not. Center char-
acteristics and practices may be associated with the differ-
ences that we are trying to identify in the Program-Specific
Reports, and therefore should not be ‘risk-adjusted away’.
Program volume is a good example: even though larger
programs may be associated with better outcomes, we
want to give due credit to larger centers that perform well
rather than adjusting away the differences associated with
volume.
The SRTR updates these Program-Specific Reports every
6 months and, in the update process, incorporates on-
going enhancements to the risk-adjustment models. At
each report, the risk adjustment is recalculated, and each
year the SRTR focuses on reviewing the entire set of risk-
adjustment covariates for one or more organs. Selection
of model covariates is based on the entire body of analyti-
cal work performed by the SRTR for the OPTN committees
and other groups, as well as input from OPTN committees.
The following factors are considered:
What are the known predictors of survival? We focus on
factors shown to be important either in SRTR analyses or in
the medical literature. Factors are included when our anal-
yses show that they have a low probability, less than 10%,
of being unassociated with outcomes. The SRTR seeks to
include in risk adjustment those variables whose estimated
effects on the outcome, at least in terms of increasing ver-
sus decreasing survival, make sense from a clinical point
of view.
Are there additional factors that we know or suspect to be
clinically significant? Based on input from medical experts
from the SRTR and the OPTN organ-specific committees,
additional variables are tested for inclusion in the models.
Some of these are only added to the models if there is
strong evidence that they affect the outcome; others may
be included regardless if the evidence is weaker but the
common wisdom is that they are important.
Are data available? Is a comparison group for this practice
or characteristic available or is the practice limited to just a
few centers? As noted earlier, we can only adjust for fac-
tors that we know about all of the patients (or donors) in
the country, and for types of operations performed at mul-
tiple transplant programs. There are many clinical features
affecting patient survival, but if these factors are not col-
lected uniformly and accurately, we cannot estimate the
effect that those features ‘usually’ have on patients, and
therefore cannot adjust for that effect.
Table 3 suggests the broad range of factors used in
risk-adjusted analyses. More detail about the models, in-
cluding lists of covariates, can be found in the techni-
cal documentation for the Program-Specific Reports at
www.ustransplant.org.
The Role of Random Chance in Experiencing
Good or Poor Outcomes
The ‘true’ ratio of observed to expected events that charac-
terizes, or would result from, a particular program’s treat-
ment practices is not known. Discovering it would require
that program to continue those exact practices on similar
samples of patients forever, and would require us to ob-
serve those outcomes. The rates we observe and show in
the Program-Specific Reports are a ‘best estimate’, based
on recent performance. The underlying events, such as
the death of a patient, are—like many daily phenomena—
affected by random chance; these estimates, too, are af-
fected by random chance.
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Table 3: Risk-adjustment factor overview, 1-year graft survival
Deceased donor Living donor
kidney kidney Liver Lung Heart
Donor demographics
Donor age X X X X X
Donor race X X X X
Donor comorbid history and other risk factors
Donor cause of death X X X X
Donor comorbid history and factors X X
Donor size X X
Expanded criteria and DCD X X
Recipient demographics
Recipient age X X X X X
Recipient insurance X X
Recipient race X X X X
Recipient sex X
Recipient diagnosis and functional status
Diagnoses X X X X X
Duration of illness X X
Functional status indexes X X X
Physiologic reserve X X X
Pretransplant treatment X X X
Previous treatments X X X X X
Recipient size X X X
Recipient sensitivity
Panel-reactive antibody X X
Donor-recipient compatibility
Blood type compatibility X
Donor relationship X
HLA mismatch X X
Weight compatibility X
Organ transfer and travel characteristics
Ischemic time X X X
Kidney pumping X
Travel distance or sharing X X
Source: SRTR, www.ustransplant.org. Note that this table is prepared as an example list, and is not exhaustive. Full listings of all covariates,
separately for each organ, time period and type of survival (graft or patient) is available at www.ustransplant.org.
There is the inherent possibility that this ‘best estimate’
may be misleading, also because of random chance. It is
important to determine the chances that the ‘true’ result—
if we knew it—would suggest no systematic difference be-
tween the outcomes observed and expected, even when
the best estimate suggests that there is a difference. Note
that the process of risk adjustment does not affect the pos-
sibility that the differences we see between observed out-
comes and expected outcomes occur because of random
chance alone, which also exists without risk adjustment. In
such cases, if the transplant program kept using the same
practices and patient protocols forever, the observed dif-
ference between observed and expected outcomes would
vanish because there is nothing systematically different
about the program’s practices, only a temporary streak of
good (or bad) luck.
In Figure 4, line 10 shows the p-value or the probability
that we would see such a difference (or more) between
observed and expected outcomes, even if there was no
systematic difference in treatment. Or to phrase it another
way, the p-value describes the chance that the observed
difference is due to chance alone, based on the sample
size (number of transplants, patients, donors) and the size
of difference observed. Given the same observed differ-
ences, a larger sample size implies a lower probability of
being due to random chance; given the same sample size,
a larger observed difference implies a lower probability that
some difference is due to random chance.
In the example case in Figure 4, the probability that the dif-
ference is as large or greater than observed due to random
chance alone and not a systematic difference in treatment
patterns is 0.469, or about 47%. In other words, even if
this transplant program has no practices that would typ-
ically lead to poorer or better outcomes, there is nearly
a 47% chance that we would see outcomes like this, or
worse. So how unlikely, or how low a p-value, do we
need in order to make conclusions about a program’s
performance?
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When making conclusions regarding a hypothesis (e.g.
classifying a program as under-performing), the level of
‘statistical significance’ depends on the acceptability of
misclassifying a center as either under- or over-performing.
For most statistical tests, a threshold of 5% probability (or
a p-value of 0.05) of random chance is applied. This implies,
for example, that a center with a ratio of observed deaths
to expected deaths of greater than 1 would be classified
as under-performing only if p < 0.05.
Note that the choice of a 5% probability threshold reflects
the decision-maker’s comfort with the possibility of mis-
classification. This comfort level might even depend upon
the intended use of the classification system: if severe and
automatic consequences result, a lower p-value thresh-
old might be used; if mere ‘further review’ or examination
of other factors results, a higher p-value threshold might
be used. This level of comfort with misclassification is re-
flected in the principles implemented by the OPTN Mem-
bership and Professional Standards Committee, described
below. For some purposes, statisticians use a more con-
servative threshold of 1% (p < 0.01). On the other hand, a
p-value of 0.10, while not ‘statistically significant’ at this ar-
bitrary level, still indicates that there is only a 10% chance
Equals Expected1
10
Centers significantly different than 
expected, p<0.05. Confidence 
intervals do not include "Equals 
Expected"
∆ Centers not significantly different 
than expected, p<0.05. Confidence 
intervals include "Equals Expected"
0
0.1
Source: SRTR Transplant Program Specific Reports, published July 2007.  
Includes transplants performed in the 2.5 years ending 6/30/2006.
Figure 6: Some centers’ standardized graft failure ratios are significantly different than expected; differences unlikely due to
random chance.
that the observed discrepancy from expected outcomes
was a random occurrence.
Another way to look at this random variation is the 95%
confidence interval (CI), shown in line 9. If this center re-
peated its treatment practices on 100 different samples of
patients with similar characteristics, the ratio of observed
to expected outcomes would probably fall in this interval
95 times. The CI is intended to be a descriptor that reflects
the precision of the estimate and, as a source of informa-
tion, serves as a complement (rather than an alternative)
to the p-value.
Figure 6 shows each program’s adjusted graft failure ra-
tio, indicating those that are significantly different from ex-
pected at a p < 0.05 level with a solid circle. While nearly
all facilities exhibit a difference between observed and ex-
pected, only a small handful of them show differences
unlikely (with less than 5% probability) to be considered
random using this test. For illustration, vertical bars show-
ing the confidence intervals are shown for several cen-
ters. Note that only when these confidence intervals do
not overlap the ‘equals expected’ line, the differences are
considered statistically significant.
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Table 4: Audiences for Program-Specific Reports
Audiences Purpose (and specific measures, if applicable)
Monitoring and process improvement
HRSA / Division of Transplantation • Identify problems with the organ transplantation system
OPTN Membership and Professional Standards • Identify individual transplant centers that may be under-performing or not following
allocation policy
Committee (MPSC) • Upon further investigation of identified centers, review membership in the OPTN
• Measures: Posttransplant outcomes; others being explored (organ acceptance
rates, transplant rates, etc.)
Regulators and other payers
CMS • Review qualification for Medicare certification for both OPOs and transplant
programs
• Measures: organs per donor by category, adjusted donation rates; posttransplant
outcomes
Private insurers • Qualify transplant programs for preferred-provider plans
• Identify individual transplant centers that may be under-performing, such that their
customers (insured patients) are not well served
• Measures: Posttransplant outcomes; others as they appear on Standardized
Request for Information (RFI)
Others
Media • Identify and publicize problems either with the current system or individual
centers, and help to explain the implications to the public
Transplant centers and clinicians • Monitor performance in comparison to other centers
• Be alerted before problems would arise to either monitoring or regulatory audience
• Provide information to their patients about the performance of the center
Patients and families • Learn about the performance of the transplant center caring for them
• If choices exist, learn about the other centers
• Find out about the general ‘prognosis’ for their disease
Source: SRTR.
Audiences and Use of These Statistics
for Performance Measurement
The development and publication of these reports is a con-
tractual requirement of the SRTR, for the intended benefit
of the transplant system as a whole. In requiring that these
statistics be publicly available, the Division of Transplanta-
tion (DOT) at the Health Resources and Services Adminis-
tration (HRSA) recognizes that many different audiences—
payers from the federal government and private sector,
oversight committees from the OPTN, transplant profes-
sionals, the media and patients and their families—will use
these data to contribute to the improved operation and out-
comes from the transplant system.
Table 4 summarizes these audiences and their uses of
these statistics.
The role of HRSA
Through the Department of Health and Human Services,
HRSA is accountable to the Congress and the public for ef-
fective oversight of the nation’s organ transplantation sys-
tem. The DOT is ultimately accountable for monitoring and
process improvement of the transplantation system.
HRSA’s objectives are to achieve the best possible out-
comes for transplant patients, by continuously improving
knowledge about patient care and maximizing operational
efficiencies. The DOT uses program-specific statistics to
be apprised of issues facing the organ transplantation sys-
tem; sometimes these issues are easier to see when
viewed at a program-specific level. HRSA’s oversight of the
OPTN system is grounded in effective performance mea-
surement using data submitted by OPTN members. Data—
as found in the OPTN/SRTR Annual Reports and SRTR
Program-Specific Reports—are used in multiple contexts,
including monitoring the effectiveness of OPTN policies;
generating short- and long-term outcome assessments;
protecting the medical safety of patients undergoing solid
organ transplantation; and, in the context of health infor-
matics, to assess practice patterns and other risk factors
to gain a better understanding of solid organ transplanta-
tion in the US.
Monitoring and process improvement
The Membership and Professional Standards Committee
(MPSC) of the OPTN works to ensure that member trans-
plant centers remain in compliance with criteria for OPTN
membership. This role includes identifying centers that are
not performing well, with the intention of helping them im-
plement corrective action or reconsidering their member-
ship. The performance measurement tools supplied by the
SRTR to the MPSC help the committee identify transplant
programs or OPOs that might require site visits or case
reviews to look more deeply into potential problems.
American Journal of Transplantation 2008; 8 (Part 2): 1012–1026 1023
Dickinson et al.
Broadly speaking, the MPSC seeks to identify the most
egregious of programs affecting the highest number of pa-
tients, including those with poor outcomes that:
(i) display a clinically significant pattern, suggesting a
higher likelihood that practices contributing to poor out-
comes might be identified, indicated by a high fraction
of excess deaths (currently, at least 50% more deaths
than expected, or O/E >1.5);
(ii) indicate that the magnitude of the problem, in terms of
potential lives saved, should be sufficient to take action
and place the center near the top of the priority list for
action; currently, this requires that at least three more
deaths are observed than were expected (i.e. O/E >
3);
(iii) are unlikely to be due to chance alone, with a probability
of less than 5% (a one-sided p-value < 0.05).
Important in the implementation of these criteria, and re-
sulting action, by the MPSC is the understanding of the
possibility that random chance and incomplete adjustment
(because of risk factors not collected in the data) affects
these outcomes. Given that the MPSC uses these crite-
ria to identify programs for further review, they are com-
fortable with a 5% probability that an identified program
is misclassified. A one-sided p-value is used for this test
because it quantifies the possibility that a result showing
poorer outcomes, rather than poorer or better outcomes, is
due to random chance. A two-sided test would be appropri-
ate if, in addition to identifying under-performing centers,
interest was also in identifying centers performing better
than average (therefore the two-sided p-value and corre-
sponding confidence interval are used on the public site).
These thresholds were set by the MPSC in an effort to iden-
tify the programs where reviews of practices might make
the biggest differences in terms of the number of patients
affected, while keeping within the resource constraints of
the OPTN’s review efforts (not selecting too many pro-
grams) and also minimizing the possibility of the burden
of review on a center where the results may likely have
occurred by random chance. Acknowledging that smaller
centers are unlikely to be reviewed under these criteria,
all smaller centers (performing nine or fewer transplants
in a 2.5-year cohort) that experience at least one adverse
event are subject to review. These thresholds are being
reviewed by the SRTR and MPSC, as is the possibility of
developing criteria that would incorporate the number of
patients and events explicitly, hence precluding the need
to classify centers as ‘small.’
More information about exactly how these three principles
are implemented, as well as their caveats, can be found in
a previously published article on this subject (1).
Although these concepts are applied to posttransplant pa-
tient and graft survival at this time, the MPSC and SRTR
are continually reviewing which additional outcomes may
be useful in identifying programs for additional scrutiny.
Currently, the MPSC is looking at different measures of
waiting list outcomes (such as the waiting list transplant
or mortality rate) and mechanisms that contribute to these
outcomes (such as organ acceptance rate) to capture this
phase of the process. Many of these outcomes are publicly
available in the Program-Specific Reports.
Regulators and Payers
The Centers for Medicare and Medicaid Services (CMS) im-
plemented similar concepts in their conditions of participa-
tion (COPs), which enable transplant programs to receive
federal funding for transplant programs services. CMS has
outlined a qualification system that is consistent with the
thresholds chosen by the MPSC and described above.
CMS will use these outcomes data in conjunction with
other data and information gathered from an onsite survey
to measure a center’s performance. The complete condi-
tions of participation can be found at http://www.cms.hhs.
gov/CFCsAndCoPs/downloads/trancenterreg2007.pdf.
Like CMS, many private insurers look to these perfor-
mance measurements to certify transplant programs as
providers of service. Many of these insurers participate in
the standardized request for information (RFI) program, de-
signed cooperatively with the OPTN Transplant Administra-
tors Committee and the SRTR. These RFIs contain a wide
range of statistics about transplant programs provided by
the SRTR, many of them consistent with those found in
the SRTR Program-Specific Reports. The focus of these
reports, of course, is the section on posttransplant out-
comes also found in Tables 10 and 11 of the transplant pro-
gram reports. Several nonparticipating insurers also look to
the public reports to find this information. Like the MPSC,
many insurers use these rates as one of several indicators,
often identifying programs where a closer look at patient
protocols and outcomes is warranted.
Other users
Other private users, such as patients and families or the
media, find the reports useful in identifying that there are,
in fact, differences among transplant programs, and that
those differences often involve trade-offs between per-
formance in different phases of the process as described
above.
For users who are interested in comparing transplant pro-
grams, the risk-adjusted ratio of observed to expected
presents a clear advantage over ranking by observed sur-
vival rate (as survival rate may reflect either success or
advantageous patient case mix). However, even ordering
by this ratio is problematic because of differences in the
variance of the estimated ratio among centers. Users
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should remember that the p-values presented do not mea-
sure the statistical significance of the difference from other
centers.
As described earlier, these statistics are not primarily in-
tended to show whether a program is statistically signif-
icantly different than another program, only that the pro-
gram is statistically different from expectations based on a
national average that accounts for patient and donor char-
acteristics. That is, while the reports may suggest that on
any one measure, such as waiting list mortality, Program
A has a higher than expected rate that is unlikely due to
chance, and Program B does not, it is not true that differ-
ences between Programs A and B carry the same likelihood
of being due to random chance. The statement that A is
probably better than expected is a more valid statement
than that A is probably better than B.
For this reason, the SRTR does not present a ‘ranking’ of
centers, or ordered list by any of the measures, and dis-
courages other users from doing so. Such a ranking might
imply that there is a meaningful difference between any
two adjacent centers (such as fifth vs. sixth on the list)
when, in fact, statistical differences among such pairs is
unlikely. This is particularly important for users who may
wish to republish portions of these reports about their own
center or a subset of centers.
Given These Performance Measures,
Should Programs Avoid Difficult Cases?
Performance measurement metrics are intended to help
identify facilities in which practices could be improved and
to identify facilities that perform well, as well as to improve
practices partly by understanding differences in achieve-
ment in different parts of the transplant process. The in-
creased use of these metrics, most notably by CMS in
their conditions of participation for federal funding, can pro-
duce mixed reaction from transplant programs and OPOs.
In an effort to avoid scrutiny from the MPSC or CMS, some
programs have suggested no longer treating difficult pa-
tients.
Very crude metrics such as target unadjusted survival rates
or donation rates, if used by oversight agencies, regulatory
or funding agencies or the general public, might logically
dissuade programs from treating difficult patients, since
it would lower these rates. However, as we have seen,
the use of risk adjustment substantially diminishes the in-
centive to avoid difficult patients and donors. While adjust-
ment cannot remove all disincentive for avoiding treating
patients with measured and reported risks, it certainly goes
well beyond the use of crude rates in removing this disin-
centive. And certainly, donors and patients with measured
risk factors should not be avoided.
Should programs use Expanded Criteria Donors?
The risk-adjustment methods described earlier allow us to
take into account many of the difficulties in treating spe-
cific kinds of patients. Earlier we described the mechanism
by which transplant with an ECD resulted in a higher ex-
pected number of graft failures or deaths. Even so, some
centers that are nearing the thresholds for review by CMS
or MPSC shy away from accepting ECDs. Table 5 outlines
the possible consequences of such decisions.
At the national level, in the top frame, the number of ob-
served graft failures equals the number of expected graft
failures, resulting in a standardized ratio of 1.00. This sug-
gests that when the risk-adjustment model is applied, we
get exactly the number of graft failures that we expect.
Note that because we adjust for ECD in these risk ad-
justments (as well as all components of ECD determi-
nation), the number of graft failures equals expected for
ECD and non-ECD (here called SCD, or Standard Criteria
Donors) alike. The number of failures per transplant for
ECDs, 0.15, is higher than that for SCDs, at 0.06: these
organs do indeed have worse outcomes, but they are
expected.
Both example centers shown also have worse outcomes
for ECD organs than they do for SCD organs when mea-
sured in unadjusted failures per transplant. However, while
Center A does not do as well as expected with its ECD or-
gans (O/E = 1.17), Center B does better than expected
(O/E = 0.84). Had Center B avoided performing these 16
ECD transplants, its standardized graft failure ratio would
have risen from 1.32 (32% excess deaths) to 1.50 (50% ex-
cess deaths), even though these 16 had a higher number
of failures per transplant.
Table 5: Effect of excluding ECD on program-specific kidney graft
survival
SCD ECD All Donors
All Centers
Transplants 33918 4155 38073
Observed graft failures 2187 630 2817
Expected graft failures 2187 630 2817
Standardized ratio (O/E) 1.00 1.00 1.00
Failures per transplant 0.06 0.15 0.07
Center A
Transplants 107 14 121
Observed graft failures 2 2 4
Expected graft failures 6.41 1.70 8.11
Standardized ratio (O/E) 0.31 1.17 0.49
Failures per transplant 0.02 0.14 0.03
Center B
Transplants 102 16 118
Observed graft failures 9 2 11
Expected graft failures 5.98 2.37 8.36
Standardized ratio (O/E) 1.50 0.84 1.32
Failures per transplant 0.09 0.13 0.09
Source: SRTR Analyses of Program-Specific Reports released July
2007.
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Center B is not uncommon: among all the programs per-
forming ECD transplants in the July 2007 release of the
Program-Specific Reports, about half (87 of 187) would
have had a higher reported standardized ratio—indicating
worse than expected outcomes—had they excluded ECD
transplants.
Conclusions and Additional Information
In this article, we have addressed and synthesized the an-
swers to many of the frequently asked questions about
the Program-Specific Reports. Armed with this informa-
tion, users of the Program-Specific Reports should under-
stand:
(i) That these reports represent a complex solid organ
transplantation system that often involves trade-offs
between different types of outcomes.
(ii) That differences do exist among programs, and ad-
vanced statistical methods do a good job at helping us
disentangle the effects of patient and donor character-
istics from the performance attributed to the program
or OPO. These methods and the data they use are im-
perfect and, therefore, only a very useful part of the
evaluation process.
(iii) That these reports are not intended to be used to com-
pare the performance of one program or OPO to an-
other, but to identify programs whose practices may
need to be corrected, avoided or emulated.
This description of the methods and concepts is intention-
ally left at an overview level. Further detail about these
methods is available from the SRTR website, in the ‘Back-
ground and Methodology’ section of the Program-Specific
Reports. Materials available there include a public-use
slideshow covering many of these concepts and others
used in the reports; technical journal articles describing
these processes in more detail (3,4); and the technical doc-
umentation to the program-specific results, which includes
current risk-adjustment model equations.
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